{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:05:21Z","timestamp":1792728321937,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1038,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016619","name":"MyoKardia, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016619","name":"MyoKardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In the EXPLORER-HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2) and New York Heart Association (NYHA) class, were greater in patients not receiving background beta-blockers than in those receiving beta-blockers. We sought to determine if the effect of background treatment was consistent across other clinically meaningful parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Subgroup analyses by beta-blocker use were performed in patients with oHCM from the EXPLORER-HCM and mavacamten long-term extension (MAVA-LTE) studies. In EXPLORER-HCM, 189 patients (75.3%) were receiving beta-blockers, and 62 (24.7%) were receiving non-dihydropyridine calcium channel blockers or no background HCM medication; 170 patients (90.4%) receiving beta-blockers had chronotropic incompetence. Improvements in peak VO2 at week 30 with mavacamten versus placebo were lower with beta-blockers (mean difference [95% confidence interval (CI)]: 1.04 [0.12, 1.95] ml\/kg\/min) than without beta-blockers (mean difference [95% CI]: 2.69 [1.29, 4.09] ml\/kg\/min); improvements in non-heart rate-dependent parameters (VE\/VCO2 slope) appeared unaffected by beta-blockers. Improvements in functional capacity parameters at week 30 with mavacamten versus placebo were independent of beta-blockade for post-exercise left ventricular outflow tract gradient (mean difference [95% CI]: \u221237.9 [\u221248.0, \u221227.9] mmHg with beta-blockers; \u221233.5 [\u221253.6, \u221213.3] mmHg without beta-blockers), proportion of patients with reduction of \u22651 NYHA class, Kansas City Cardiomyopathy Questionnaire clinical summary scores and N-terminal pro-B-type natriuretic peptide. Mavacamten benefits were reproduced and maintained in MAVA-LTE regardless of beta-blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mavacamten improved measures of functional capacity, left ventricular outflow tract obstruction, symptom burden and biomarkers in patients with HCM regardless of beta-blocker use. Beta-blocker use was often associated with chronotropic incompetence, affecting peak VO2 and other heart rate-dependent measures, but had minimal impact on heart rate-independent measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2737","type":"journal-article","created":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T23:30:55Z","timestamp":1668987055000},"page":"260-270","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Effect of Beta-Blocker Therapy on the Response to Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-3022","authenticated-orcid":false,"given":"Matthew T.","family":"Wheeler","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Center for Inherited Cardiovascular Disease, Stanford University , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3383-3984","authenticated-orcid":false,"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[{"name":"University College London & St. Bartholomew's Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila M.","family":"Hegde","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K.","family":"Lakdawala","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Myers","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Veterans Affairs Palo Alto Healthcare System , Palo Alto, CA ,","place":["USA"]},{"name":"Stanford University , Palo Alto, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Sehnert","sequence":"additional","affiliation":[{"name":"MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb , Brisbane, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay M.","family":"Edelberg","sequence":"additional","affiliation":[{"name":"MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb , Brisbane, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Li","sequence":"additional","affiliation":[{"name":"MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb , Brisbane, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unity, Azienda Ospedaliera Universitaria Careggi and University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"2026010913083420800_ejhf2737-bib-0001","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913083420800_ejhf2737-bib-0002","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026010913083420800_ejhf2737-bib-0003","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913083420800_ejhf2737-bib-0004","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"2026010913083420800_ejhf2737-bib-0005","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913083420800_ejhf2737-bib-0006","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"2026010913083420800_ejhf2737-bib-0007","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"2026010913083420800_ejhf2737-bib-0008","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026010913083420800_ejhf2737-bib-0009","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00007256-198805040-00002","article-title":"Beta-adrenoceptor blockade and exercise. An update","volume":"5","author":"Van Baak","year":"1988","journal-title":"Sports Med"},{"key":"2026010913083420800_ejhf2737-bib-0010","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913083420800_ejhf2737-bib-0011","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/healthcare9020212","article-title":"Chronotropic incompetence limits aerobic exercise capacity in patients taking beta-blockers: real-life observation of consecutive patients","volume":"9","author":"Smarz","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"2026010913083420800_ejhf2737-bib-0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026010913083420800_ejhf2737-bib-0013","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/CIR.0b013e318223e230","article-title":"ACCF\/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"key":"2026010913083420800_ejhf2737-bib-0014","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913083420800_ejhf2737-bib-0015","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026010913083420800_ejhf2737-bib-0016","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913083420800_ejhf2737-bib-0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2010.08.026","article-title":"Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy","volume":"153","author":"Efthimiadis","year":"2011","journal-title":"Int J Cardiol"},{"key":"2026010913083420800_ejhf2737-bib-0018","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/MCA.0000000000000610","article-title":"\u03b2-Blockers in myocardial infarction and coronary artery disease with a preserved ejection fraction: recommendations, mechanisms, and concerns","volume":"29","author":"Nambiar","year":"2018","journal-title":"Coron Artery Dis"},{"key":"2026010913083420800_ejhf2737-bib-0019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2459\/JCM.0000000000000662","article-title":"Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results","volume":"19","author":"Peyracchia","year":"2018","journal-title":"J Cardiovasc Med"},{"key":"2026010913083420800_ejhf2737-bib-0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1074248416679733","article-title":"Angina and its management","volume":"22","author":"Kloner","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026010913083420800_ejhf2737-bib-0021","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"2026010913083420800_ejhf2737-bib-0022","first-page":"e210","article-title":"2017 AHA\/ACC\/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation"},{"key":"2026010913083420800_ejhf2737-bib-0023","volume-title":"Effect on maximal functional capacity of beta-blockers withdrawal in heart failure with preserved ejection fraction and chronotropic incompetence: PRESERVE-HR trial","author":"Seller"},{"issue":"1","key":"2026010913083420800_ejhf2737-bib-0024","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1513\/AnnalsATS.201611-884FR","article-title":"Cardiopulmonary exercise test in hypertrophic cardiomyopathy","volume":"14","author":"Magr\u00ec","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026010913083420800_ejhf2737-bib-0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.HCR.0000320071.89093.d6","article-title":"The ventilatory classification system effectively predicts hospitalization in patients with heart failure","volume":"28","author":"Arena","year":"2008","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"2026010913083420800_ejhf2737-bib-0026","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1161\/CIRCULATIONAHA.107.686576","article-title":"Development of a ventilatory classification system in patients with heart failure","volume":"115","author":"Arena","year":"2007","journal-title":"Circulation"},{"key":"2026010913083420800_ejhf2737-bib-0027","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/euhj.1999.1863","article-title":"Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE\/VCO2 slope and peak VO2","volume":"21","author":"Francis","year":"2000","journal-title":"Eur Heart J"},{"key":"2026010913083420800_ejhf2737-bib-0028","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1161\/CIRCULATIONAHA.105.594218","article-title":"Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival","volume":"113","author":"Dimopoulos","year":"2006","journal-title":"Circulation"},{"key":"2026010913083420800_ejhf2737-bib-0029","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.healun.2005.11.448","article-title":"Determining the best ventilatory efficiency measure to predict mortality in patients with heart failure","volume":"25","author":"Bard","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"2026010913083420800_ejhf2737-bib-0030","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cardfail.2017.07.397","article-title":"Clinical and hemodynamic correlates and prognostic value of VE\/VCO2 slope in patients with heart failure with preserved ejection fraction and pulmonary hypertension","volume":"23","author":"Klaassen","year":"2017","journal-title":"J Card Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.2737","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/2\/260\/65562221\/eurjhf_25_2_260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/2\/260\/65562221\/eurjhf_25_2_260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:10:32Z","timestamp":1767982232000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/2\/260\/8341738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,1]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2737","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2]]},"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"2022-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}